相关临床试验
1138
1035 进行中
药物批准
35
批准总数
监管机构
4
监管机构数
成立时间
N/A
招募中
21
1.9%
暂停
1
0.1%
撤回
1
0.1%
进行中（未招募）
1010
88.8%
已完成
58
5.1%
尚未招募
25
2.2%
- The global mRNA synthesis raw materials market was valued at USD 1.85 billion in 2025 and is projected to reach USD 3.89 billion by 2035, growing at a CAGR of 7.70%. - Nucleotides led the market by type with an approximate 38.50% share in 2025, while vaccine production dominated applications at roughly 85.00% of revenue. - North America held the largest regional share at approximately 38.50%, with the U.S. accounting for about 85.80% of North American revenue. - Growth is driven by expanding mRNA vaccine and therapeutic pipelines, rising demand for GMP-grade raw materials, and increasing adoption of GMP manufacturing practices.
- The global molecular diagnostics market is projected to grow from USD 19.48 billion in 2025 to USD 30.74 billion by 2030, at a CAGR of 9.6%, according to MarketsandMarkets. - PCR and real-time PCR technologies dominate the market with a 42.54% revenue share, while sequencing-based testing is the fastest-growing segment due to personalized medicine adoption. - North America leads the global market with a 38.49% share, while Asia Pacific is the fastest-growing region with an estimated CAGR of 24.45% through 2035. - Key players including Roche, Danaher, Abbott, and Thermo Fisher are investing in automation, AI-powered analytics, and multiplex assay development to strengthen competitive positioning.
- The global oncology companion diagnostic market was valued at USD 5.09 billion in 2025 and is projected to reach USD 14.65 billion by 2035, growing at a CAGR of 11.09%. - North America held the largest revenue share at over 42.86% in 2025, with the U.S. market alone valued at USD 2.17 billion, fueled by FDA regulatory leadership in precision oncology. - Non-small cell lung cancer (NSCLC) dominated the market with approximately 31% share in 2025, while breast cancer represents the fastest-growing cancer type segment. - Next-generation sequencing (NGS) is the fastest-growing technology segment at a CAGR of 12.64%, reflecting increasing demand for comprehensive genomic profiling and multi-gene testing.
- Strategic alliances in the biomarker industry have accelerated from 2019 to 2025, driven by growing demand for precision medicine, companion diagnostics, and targeted therapies. - Partnerships are dominating the biomarker market, with companies leveraging collaborations to accelerate development and expand market reach through licensing, acquisitions, and strategic alliances. - Rising incidence of chronic diseases like cancer and diabetes, combined with advances in omics and imaging technologies, is fueling increased investment in biomarker-related deals. - Biomarkers are transforming oncology care by enabling companion diagnostics that allow targeted therapies to be administered only to patients likely to benefit, improving efficacy while reducing costs.
- The global biotechnology market is projected to surge from $1.55 trillion in 2024 to $5.71 trillion by 2034, representing a robust 13.9% compound annual growth rate. - Tissue engineering and regeneration technologies captured the largest market share at 19.17% in 2024, while chromatography is emerging as the fastest-growing segment with a 15.1% CAGR. - North America dominates the market with 37.42% share in 2024, while Asia Pacific is positioned as the fastest-growing region with a 14.8% CAGR driven by demographic strength and healthcare expansion. - Bio-pharmacy applications lead the market with 42% share in 2024, fueled by increasing demand for biologics and personalized treatments over traditional chemical-based drugs.
- DelveInsight's 2025 pipeline analysis reveals 8+ key companies are developing 10+ novel Graves Disease treatment therapies across various clinical development phases. - Recent regulatory milestones include Amgen's TEPEZZA approval by UK MHRA for thyroid eye disease and FDA's breakthrough therapy designation for Viridian's veligrotug. - Emerging therapies targeting IGF-1R pathway show clinical promise, with Sling Therapeutics' linsitinib demonstrating favorable safety profile in over 900 patients across 15 trials. - Pipeline includes diverse therapeutic approaches spanning monoclonal antibodies, small molecules, and gene therapy with multiple routes of administration under investigation.
